Latest news
EyeWorld Weekly, August 7, 2026 - EyeWorldEyeWorld · Fri, 07 Aug 2026 16:04:01 GMTAhead‑of‑Schedule DME Trial Enrollment Could Be A Game Changer For EyePoint (EYPT) - simplywall.stsimplywall.st · Wed, 05 Aug 2026 05:24:44 GMTEyePoint Completes Enrollment in Phase 3 Duravyu Trials for DME Ahead of Schedule - Eyewire+Eyewire+ · Fri, 31 Jul 2026 13:07:27 GMTEyePoint Completes Enrollment of Both Pivotal Phase 3 - GlobeNewswireGlobeNewswire · Thu, 30 Jul 2026 11:00:00 GMTEyePoint, Inc. (Nasdaq: EYPT) finishes Phase 3 DME enrollment, sets 2027 data goal - Stock TitanStock Titan · Thu, 30 Jul 2026 07:00:00 GMTEyePoint completes enrollment for Phase 3 trials of DURAVYU for diabetic macular edema, data expected Q4 2027 - PluangPluang · Thu, 30 Jul 2026 07:00:00 GMT